Protein may predict chemotherapy response in osteosarcoma

Share this article:

The expression of the P16 protein, which inhibits cell growth, may be a useful biomarker for predicting how osteosarcoma will respond to standard chemotherapy, researchers concluded after finding that P16 expression significantly correlates with chemotherapy response among patients with that form of cancer.

As a team led by Dariusz Borys of the University of California–Davis Department of Pathology and Laboratory Medicine in Sacramento explained in Human Pathology, pathologic response to neoadjuvant chemotherapy is highly correlated with survival among persons with osteosarcoma, the most common bone cancer in children. (Osteosarcoma can also affect people after age 60 years.) However, there are no established molecular markers to predict response to this treatment.

The research group analyzed data from pretreatment biopsy specimens of 40 patients with osteosarcoma. The median age of the patients was 15 years (range, 9 to 75 years), and 35% of the biopsied tumors were located in the femur. P16 expression was found to be present in 62% of the specimens.

Following chemotherapy, during surgery to remove the tumor, specimens were again collected and analyzed. Median tumor necrosis was 90%, and 55% of patients experienced “good” chemotherapy response, defined as tumor necrosis of at least 90%. These patients were significantly more likely to have had tumors that expressed the P16 protein.

After the researchers controlled for patient age and gender and for tumor subtype and location, P16 expression was independently associated with chemotherapy response.

.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Survival equivalent with cetuximab or bevacizumab in metastatic colorectal cancer

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.

Some aggressive cancers may respond to anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.

Pain and itch may indicate skin cancer

Pain and itch may indicate skin cancer

Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study.